CytomX Therapeutics's total assets for Q1 2026 were $359.36M, an increase of 137.10% from the previous quarter. CTMX total liabilities were $39.41M for the fiscal quarter, a -25.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.